Zaritsky A
University of North Carolina School of Medicine, Chapel Hill.
Drugs. 1989 Mar;37(3):356-74. doi: 10.2165/00003495-198937030-00005.
In contrast to adults, cardiopulmonary arrest in infants and children is rarely an acute, primary cardiac event. Instead, it is often the terminal event in a progressive deterioration of respiratory or circulatory function. Successful resuscitation from cardiac arrest therefore is unusual in the paediatric patient and most survivors have persistent neurological impairment. Rapid vascular access and recall of drug dosages are major obstacles in treating paediatric emergencies. This paper reviews vascular access and alternative drug delivery methods. The endotracheal and intraosseous routes provide alternative sites for drug delivery, but the optimal doses and methods of drug administration via these routes are unknown. Indeed, although great progress in cardiopulmonary resuscitation (CPR) research has been made over the past 10 years, there are only limited data on paediatric arrest mechanisms and drug treatment. In this paper, recommended dosages and mechanisms of action of drugs useful during cardiopulmonary resuscitation are reviewed, highlighting recent data which suggest that changes in current drug recommendations may be needed. To avoid delays in management, precalculated tables of drugs should be readily available in emergency departments and other care areas where paediatric cases are likely to be seen. Adrenaline (epinephrine) remains the drug of choice in a cardiac arrest, but the most effective dose may be higher than currently used. Treatment of acidosis during the arrest concentrates on restoration of ventilation and blood flow and not on bicarbonate administration. In the post-arrest setting increasing data suggest bicarbonate may not be beneficial and may actually be detrimental. Calcium and atropine also have relatively minor roles in resuscitation pharmacology. Calcium is only indicated to treat hypocalcaemia, counteract the effects of hyperkalaemia or hypermagnesaemia, or reverse calcium channel blocker toxicity. Finally, the role of isoprenaline (isoproterenol), dopamine, dobutamine and adrenaline infusions to restore or maintain cardiovascular stability post-arrest is reviewed.
与成人不同,婴儿和儿童的心肺骤停很少是急性原发性心脏事件。相反,它通常是呼吸或循环功能进行性恶化的终末事件。因此,儿科患者从心脏骤停中成功复苏并不常见,大多数幸存者都有持续性神经功能障碍。快速建立血管通路和准确记住药物剂量是治疗儿科急症的主要障碍。本文综述了血管通路和替代药物给药方法。气管内和骨内途径为药物给药提供了替代部位,但通过这些途径给药的最佳剂量和方法尚不清楚。事实上,尽管在过去10年里心肺复苏(CPR)研究取得了很大进展,但关于儿科心脏骤停机制和药物治疗的数据仍然有限。本文回顾了心肺复苏期间有用药物的推荐剂量和作用机制,强调了最近的数据,这些数据表明可能需要改变目前的药物推荐。为避免治疗延误,急诊科和其他可能会遇到儿科病例的护理区域应随时提供预先计算好的药物剂量表。肾上腺素仍然是心脏骤停时的首选药物,但最有效的剂量可能高于目前使用的剂量。心脏骤停期间酸中毒的治疗重点是恢复通气和血流,而不是给予碳酸氢盐。在心脏骤停后,越来越多的数据表明碳酸氢盐可能没有益处,实际上可能有害。钙和阿托品在复苏药理学中的作用也相对较小。钙仅用于治疗低钙血症、对抗高钾血症或高镁血症的影响,或逆转钙通道阻滞剂中毒。最后,本文综述了异丙肾上腺素、多巴胺、多巴酚丁胺和肾上腺素输注在心脏骤停后恢复或维持心血管稳定性方面的作用。